Literature DB >> 3367302

Pyrimidine dideoxyribonucleosides: selectivity of penetration into cerebrospinal fluid.

J M Collins1, R W Klecker, J A Kelley, J S Roth, C L McCully, F M Balis, D G Poplack.   

Abstract

Cerebrospinal fluid (CSF)/plasma ratios of 1 to 30% were obtained in rhesus monkeys for the 3'-azido- and 2',3'-dideoxy-analogs of thymidine, deoxycytidine and deoxyuridine. Penetration of thymidine and deoxyuridine analogs was much greater than for deoxycytidine analogs. Octanol/buffer partition coefficients varied more than 30-fold, but did not correlate with CSF entry. Plasma protein binding was insignificant for all compounds. The presence or absence of the azido group at position 3' did not appear to influence the extent of CSF penetration. Although we do not fully understand the mechanistic basis for the penetration of these nucleosides into the CSF, it is apparent that the structural specificity is related more closely to the nucleobase than the sugar. Based upon elimination rates from the CSF after direct intrathecal injection, the differences in net penetration are determined by influx rather than efflux processes.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3367302

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  20 in total

Review 1.  Clinical pharmacokinetics of zidovudine. An overview of current data.

Authors:  J M Collins; J D Unadkat
Journal:  Clin Pharmacokinet       Date:  1989-07       Impact factor: 6.447

2.  1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity.

Authors:  S M Daluge; S S Good; M B Faletto; W H Miller; M H St Clair; L R Boone; M Tisdale; N R Parry; J E Reardon; R E Dornsife; D R Averett; T A Krenitsky
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

3.  Pharmacokinetics of (-)-beta-D-2-aminopurine dioxolane and (-)-beta-D-2-amino-6-chloropurine dioxolane and their antiviral metabolite (-)-beta-D-dioxolane guanine in rhesus monkeys.

Authors:  H Chen; F D Boudinot; C K Chu; H M Mcclure; R F Schinazi
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

Review 4.  CSF penetration by antiretroviral drugs.

Authors:  Christine Eisfeld; Doris Reichelt; Stefan Evers; Ingo Husstedt
Journal:  CNS Drugs       Date:  2013-01       Impact factor: 5.749

Review 5.  Clinical pharmacology of zidovudine and other 2',3'-dideoxynucleoside analogues.

Authors:  F Kamali
Journal:  Clin Investig       Date:  1993-05

Review 6.  Zidovudine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  H D Langtry; D M Campoli-Richards
Journal:  Drugs       Date:  1989-04       Impact factor: 9.546

7.  Pharmacokinetics and metabolism of racemic 2',3'-dideoxy-5-fluoro-3'-thiacytidine in rhesus monkeys.

Authors:  R F Schinazi; F D Boudinot; S S Ibrahim; C Manning; H M McClure; D C Liotta
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

8.  Efflux of zidovudine and 2',3'-dideoxyinosine out of the cerebrospinal fluid when administered alone and in combination to Macaca nemestrina.

Authors:  T Tuntland; R J Ravasco; S al-Habet; J D Unadkat
Journal:  Pharm Res       Date:  1994-02       Impact factor: 4.200

9.  Serum and cerebrospinal fluid pharmacokinetics of intravenous and oral lamivudine in human immunodeficiency virus-infected children.

Authors:  B U Mueller; L L Lewis; G J Yuen; M Farley; A Keller; J A Church; J C Goldsmith; D J Venzon; M Rubin; P A Pizzo; F M Balis
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

Review 10.  Zalcitabine. A review of its pharmacology and clinical potential in acquired immunodeficiency syndrome (AIDS).

Authors:  R Whittington; R N Brogden
Journal:  Drugs       Date:  1992-10       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.